Fibrocell Science, Inc. Enters into Agreement to Sell Majority Ownership Stake in Agera Laboratories for $0.85 Million
June 08 2012 - 9:00AM
Business Wire
Fibrocell Science, Inc. (OTCBB:FCSC) announced today that it has
entered into a definitive agreement to sell its majority ownership
stake in Agera Laboratories, a skincare company offering
anti-aging, pigmentation and acne treatment products, to Rohto
Pharmaceutical Co., Ltd. for $0.85 million. Within ten days, $0.40
million is to be paid and the remaining balance will be paid at the
closing of the transaction, which is expected by August 31, 2012.
Fibrocell acquired a 57 percent ownership stake in Agera
Laboratories in August 2006.
“With the recent FDA approval of our lead product LAVIV, we are
now focusing our efforts on the commercialization of LAVIV and the
pursuit of additional indications for the product,” said David
Pernock, Fibrocell’s Chairman and CEO.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTCBB:FCSC) is an autologous cellular
therapeutic company focused on the development of innovative
products for aesthetic, medical and scientific applications.
Fibrocell Science is committed to advancing the scientific, medical
and commercial potential of autologous skin and tissue, as well as
its innovative cellular processing technology and manufacturing
excellence. For additional information, please visit
www.fibrocellscience.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and the
provisions of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. While management has based any forward-looking statements
contained herein on its current expectations, the information on
which such expectations were based may change. These
forward-looking statements rely on a number of assumptions
concerning future events and are subject to a number of risks,
uncertainties, and other factors, many of which are outside of the
Company's control, that could cause actual results to materially
differ from such statements. Such risks, uncertainties, and other
factors include, but are not necessarily limited to, those set
forth under Item 1A "Risk Factors" in the Company's Annual Report
on Form 10-K for the year ended December 31, 2011, as updated in
"Item 1A. Risk Factors" in the Company's Quarterly Reports on Form
10-Q filed since the annual report. The Company operates in a
highly competitive and rapidly changing environment, thus new or
unforeseen risks may arise. Accordingly, investors should not place
any reliance on forward-looking statements as a prediction of
actual results. The Company disclaims any intention to, and
undertakes no obligation to, update or revise any forward-looking
statements. Readers are also urged to carefully review and consider
the other various disclosures in the Company's public filings with
the SEC.